MMR (Measles,Mumps,Rubella) Vaccine Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) study
Vaccine. 2022 Apr 28:S0264-410X(22)00437-6. doi: 10.1016/j.vaccine.2022.04.011. Online ahead of print.ABSTRACTWe aimed to determine population immunity to measles in Canada, and to assess the risk of future outbreaks. We tested 11,176 sera from Cycles 2 (2009-2011) and 3 (2011-2013) cohorts from the biobank of Statistics Canada's Canadian Health Measures Survey (CHMS) using the BioPlex 2220 MMRV IgG assay. We then tested all BioPlex negative and equivocal samples using a more sensitive Plaque Reduction Neutralization Test (PRNT). We determined the weighted proportion of positive, equivocal, and negative samples by age, sex...
Source: Vaccine - May 1, 2022 Category: Allergy & Immunology Authors: Selma Osman Natasha Crowcroft Elizabeth McLachlan Todd Hatchette Carol Perez-Iratxeta Eugene Joh James Wright Scott A Halperin Shelley Deeks Sarah Wilson Sarah Buchan Brian Ward Jonathan Gubbay Marc Brisson Bouchra Serhir Alberto Severini Shelly Bolotin Source Type: research

Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions
CONCLUSION: Use of MMRV at second dose is not associated with an increased risk of FC compared to MMR + V or MMR, irrespective of age, sex, history of FC, or type of first dose vaccine.PMID:35232594 | DOI:10.1016/j.vaccine.2022.02.072 (Source: Vaccine)
Source: Vaccine - March 2, 2022 Category: Allergy & Immunology Authors: Wiebke Sch äfer Tammo Reinders Tania Schink Source Type: research

Mild Herpes Zoster After MMRV Vaccination
Dtsch Arztebl Int. 2021 Dec 3;118(48):823. doi: 10.3238/arztebl.m2021.0183.NO ABSTRACTPMID:35191824 | DOI:10.3238/arztebl.m2021.0183 (Source: Deutsches Arzteblatt International)
Source: Deutsches Arzteblatt International - February 22, 2022 Category: General Medicine Authors: Marc Bienias Reinhard Berner Source Type: research

Mild Herpes Zoster After MMRV Vaccination
Dtsch Arztebl Int. 2021 Dec 3;118(48):823. doi: 10.3238/arztebl.m2021.0183.NO ABSTRACTPMID:35191824 | DOI:10.3238/arztebl.m2021.0183 (Source: Herpes)
Source: Herpes - February 22, 2022 Category: Infectious Diseases Authors: Marc Bienias Reinhard Berner Source Type: research

Vaccines for measles, mumps, rubella, and varicella in children
CONCLUSIONS: Existing evidence on the safety and effectiveness of MMR/MMRV vaccines support their use for mass immunisation. Campaigns aimed at global eradication should assess epidemiological and socioeconomic situations of the countries as well as the capacity to achieve high vaccination coverage. More evidence is needed to assess whether the protective effect of MMR/MMRV could wane with time since immunisation.PMID:34806766 | DOI:10.1002/14651858.CD004407.pub5 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - November 22, 2021 Category: General Medicine Authors: Carlo Di Pietrantonj Alessandro Rivetti Pasquale Marchione Maria Grazia Debalini Vittorio Demicheli Source Type: research

Management care improvement of people living with HIV: definition of a targeted clinical pathway in a University Hospital of South Italy
CONCLUSIONS: The undertook clinical pathway showed the relevance of specific management of these patients and the need to increase the vaccination offer.PMID:34487078 | DOI:10.23750/abm.v92i4.11425 (Source: Acta Bio-Medica : Atenei Parmensis)
Source: Acta Bio-Medica : Atenei Parmensis - September 6, 2021 Category: General Medicine Authors: Smeralda D'Amato Giovanni Francesco Pellican ò Giuseppe Nunnari Franco Fedele Raffaele Squeri Francesco Mazzitelli Flavia D'Andrea Daniele Maisano Raffaele Squeri Cristina Genovese Source Type: research

Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries
CONCLUSIONS: Our results indicated that two doses of varicella zoster virus-containing vaccine provided better protection than one dose against varicella and induced antibody responses that persisted 10 years post-vaccination.PMID:33858718 | DOI:10.1016/j.vaccine.2021.03.085 (Source: Vaccine)
Source: Vaccine - April 16, 2021 Category: Allergy & Immunology Authors: Roman Prymula Michael Povey Jerzy Brzostek Hana Cabrnochova Roman Chlibek Hanna Czajka Giedra Leviniene Sorin Man Mihai Neamtu Petr Pazdiora Doina Plesca Renata Ruzkova Maria Stefkovicova Vytautas Usonis Daniela Verdanova Jacek Wysocki Giacomo Casabona Md Source Type: research